Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Chemotherapy in Advanced Ovarian Cancer
NCT03611179Phase 2Unknown
- Start
- Sep 2018
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of bevacizumab in ovarian cancer. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03611179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611179.